Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000557529 | SCV000650996 | likely benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2023-12-17 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003144353 | SCV003833127 | uncertain significance | not provided | 2019-08-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004619335 | SCV005117821 | uncertain significance | Cardiovascular phenotype | 2024-05-17 | criteria provided, single submitter | clinical testing | The p.S1217C variant (also known as c.3649A>T), located in coding exon 21 of the FLNC gene, results from an A to T substitution at nucleotide position 3649. The serine at codon 1217 is replaced by cysteine, an amino acid with dissimilar properties. This alteration has been reported in a neuromuscular disease cohort (Westra D et al. J Neuromuscul Dis, 2019;6:241-258). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |